Mineralys Therapeutics Files Q1 2025 10-Q
Ticker: MLYS · Form: 10-Q · Filed: May 12, 2025 · CIK: 1933414
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Mineralys Therapeutics filed its Q1 2025 10-Q, check financials.
AI Summary
Mineralys Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, incorporated in Delaware, operates in the Pharmaceutical Preparations sector. Its principal business address is in Radnor, Pennsylvania.
Why It Matters
This filing provides investors with the latest financial performance and operational details for Mineralys Therapeutics, Inc. during the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a routine quarterly filing with no immediate red flags or significant new disclosures.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- Radnor, Pennsylvania (location) — Company's business address
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the reporting period for this 10-Q filing?
The 10-Q filing is for the period ending March 31, 2025.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Mineralys Therapeutics, Inc. located?
The company's business and mailing address is 150 N. Radnor Chester Road, Suite F200, Radnor, PA 19087.
What is the SEC file number for Mineralys Therapeutics, Inc.?
The SEC file number is 001-41614.
When was this 10-Q filing submitted?
This 10-Q filing was submitted on May 12, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Mineralys Therapeutics, Inc. (MLYS).